Sign up to save your podcasts
Or
Share From Paint to Biotech: Turning Biology into a Predictive Science, The Story of Seven Bridges, Totient, and AbSci with James Sietstra and Deniz Kural
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
From Paint to Biotech: Turning Biology into a Predictive Science, The Story of Seven Bridges, Totient, and AbSci with James Sietstra and Deniz Kural
We discuss James' and Deniz's careers from how they first met to founding Seven Bridges and Totient and now building AbSci after Totient was recently acquired. With experience leading teams in the 100s spanning genomics and SaaS to drug development and even paint from James' childhood entrepreneurial pursuits, both have an incredible amount of wisdom on scaling technology companies. We touch on AbSci's unique model of accelerating and lowering the barriers for biologics development and talk about the finding the right platform-partner fit. Some favorite quotes of mine after this conversation are: during any negotiations, "competition is highly important for deals" and Deniz's experience of "seeing the future early but unevenly distributed" just as sequencing costs began coming down outpacing Moore's Law.
View all episodes
By Joshua Elkington
5
22 ratings
We discuss James' and Deniz's careers from how they first met to founding Seven Bridges and Totient and now building AbSci after Totient was recently acquired. With experience leading teams in the 100s spanning genomics and SaaS to drug development and even paint from James' childhood entrepreneurial pursuits, both have an incredible amount of wisdom on scaling technology companies. We touch on AbSci's unique model of accelerating and lowering the barriers for biologics development and talk about the finding the right platform-partner fit. Some favorite quotes of mine after this conversation are: during any negotiations, "competition is highly important for deals" and Deniz's experience of "seeing the future early but unevenly distributed" just as sequencing costs began coming down outpacing Moore's Law.
More shows like Axial Podcast
View all
HBR IdeaCast
1,830 Listeners
Masters in Business
2,172 Listeners
The Bio Report
39 Listeners
Conversations with Tyler
2,389 Listeners
Founders
1,877 Listeners
The Long Run with Luke Timmerman
122 Listeners
The Readout Loud
317 Listeners
Biotech 2050 Podcast
59 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
9,095 Listeners
Business Of Biotech
88 Listeners
BioCentury This Week
29 Listeners
Biotech Hangout
10 Listeners
No Priors: Artificial Intelligence | Technology | Startups
121 Listeners
The Top Line
11 Listeners
Money Stuff: The Podcast
371 Listeners